Movement State-dependent Adaptive DBS for PD

StatusEnrolling by Invitation
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years 7 months later Sep 1, 2026 → Apr 1, 2030
See other at-risk trials from Doris Wang, MD, PhD

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 1, 2026 to Apr 1, 2030 Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 9 entries
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Collaborators: details revised at 1 of 2 entries
    • Publications: details revised at 3 of 3 entries
  2. Primary completion pushed from Apr 1, 2026 to Sep 1, 2026v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center clinical study aiming to improve gait functions in patients with Parkinson's Disease (PD) by using adaptive neurostimulation to the pallidum. The investigators will use a bidirectional deep brain stimulation device with sensing and stimulation capabilities to 1) identify neural biomarkers to detect the onset of walking by recording neural activities from the motor cortical areas and the globus pallidus, 2) understand the impacts of changes in DBS parameters on gait kinematics and optimize setting parameters for enhancing walking performance, 3) develop a movement state-dependent adaptive deep brain stimulation (DBS) paradigm to automatically switch stimulation settings according to different movement states (i.e., walking vs non-walking). The proposed therapy will deliver personalized neurostimulation based on individual physiological biomarkers to enhance gait function in patients with PD. 6 patients with idiopathic Parkinson's disease who have already been implanted with the Medtronic Summit RC+S device will be enrolled in this study.
Trial Details
NCT Number NCT07424508
Lead Sponsor Doris Wang, MD, PhD
Collaborators: Michael J. Fox Foundation for Parkinson's Research, Burroughs Wellcome
Conditions
(from sponsor)		 Parkinson's Disease (PD)
Related terms Parkinson Disease
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov